Board Member
Crescent Biopharma, Inc. (CBIO)Board Member
Dianthus Therapeutics, Inc. (DNTH)Equibles does not estimate personal net worth.
Get an email with a short summary when Crescent Biopharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get CBIO alertsJonathan Violin is recorded as Board Member at Crescent Biopharma, Inc. (CBIO), COO at Viridian Therapeutics, Inc.\DE (VRDN) since October 27, 2020 and Board Member at Dianthus Therapeutics, Inc. (DNTH) since January 1, 2019. The newest filing on record that lists Jonathan Violin as Board Member at Crescent Biopharma, Inc. (CBIO) is dated April 21, 2026. The newest filing on record that lists Jonathan Violin as Board Member at Dianthus Therapeutics, Inc. (DNTH) is dated April 9, 2026. Crescent Biopharma, Inc. reported in an 8-K filed June 18, 2025 that Jonathan Violin was appointed director, effective June 13, 2025. Viridian Therapeutics, Inc.\DE reported in an 8-K filed February 6, 2023 that Jonathan Violin resigned as member of the Board of Directors, effective February 6, 2023. Viridian Therapeutics, Inc.\DE reported in an 8-K filed February 6, 2023 that Jonathan Violin was terminated as President and Chief Executive Officer, effective February 6, 2023. The proxy statement of Viridian Therapeutics, Inc.\DE reports total compensation of $2,211,072 for Jonathan Violin in fiscal 2023, including a base salary of $59,209. Disclosed compensation is on record for 3 fiscal years. Jonathan Violin has spoken on 4 earnings calls across 1 company, most recently for Viridian Therapeutics, Inc.\DE on August 15, 2022. Viridian Therapeutics, Inc.\DE is classified in the Biotechnology industry within the Healthcare sector. Crescent Biopharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Viridian Therapeutics, Inc.\DE includes Scott Myers (CEO and Board Member), Stephen Mahoney (CEO and Board Member), Tomas Kiselak (Chairman) and 7 others.
“On June 13, 2025, the Board decreased its size from eight to six members and appointed the following six individuals to the Board: Peter Harwin, Alexandra Balcom, Joshua Brumm, David Lubner, Susan Moran and Jonathan Violin.”
“Dr. Violin shall cease to serve as a member of the Board of Directors of the Company (the "Board") effective as of the Separation Date.”
“We're excited to share some remarkable data from our ongoing trial of VRDN-001 for the treatment of Thyroid Eye Disease or TED. The results are frankly outstanding.”
“I'm also joined today by Kristian Humer, our Chief Financial Officer and Chief Business Officer. We'll begin with a brief update on the business, including recent and upcoming milestones and the progress we're making in advancing our lead candidates for Thyroid Eye Disease or TED.”
“I’m also joined today by Kristian Humer, our Chief Financial Officer and Chief Business Officer. I’ll begin with a brief overview of the business, our recent milestones as well as a review of our pipeline, including progress we’ve made in advancing our lead candidates for thyroid eye disease.”
“I'm joined today by Barrett Katz, our Chief Medical Officer; and Jason Leverone, our Chief Financial Officer. I'll begin with a brief overview of the business and the development pipeline, highlighting key progress we've made in recent months.”
2020-10-27–present
2019-01-01–present
Last confirmed April 9, 2026
Start not stated–present
Last confirmed April 21, 2026
Start not stated–2023-02-06
Start not stated–2023-02-06
Biotechnology · Healthcare
COO
2020-10-27–present
Biotechnology · Healthcare
Board Member
2019-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Viridian Therapeutics, Inc.\DE (VRDN) | Former President, Chief Executive Officer and Director | $59,209 | $2,211,072 |
| 2022 | Viridian Therapeutics, Inc.\DE (VRDN) | Former President, Chief Executive Officer and Director | $601,200 | $4,646,740 |
| 2021 | Viridian Therapeutics, Inc.\DE (VRDN) | Former President, Chief Executive Officer and Director | $567,000 | $17,408,538 |
